TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 9.2 YEARS OF SAFETY DATA FROM THE GLOBAL CLINICAL PROGRAMME

Julian Panés  ¹     Geert R. D’Haens  ²     Bruce E. Sands  ³     Siew Chien Ng  ⁴     Nervin Lawendy  ⁵     Nicole Kulisek  ⁵     Xiang Guo  ⁵     Joseph Wu  ⁶     Ivana Vranic  ⁷     Remo Panaccione  ⁸     Severine Vermeire  ^9    
1 Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
² Amsterdam University Medical Centers, Amsterdam, Netherlands
³ Icahn School of Medicine at Mount Sinai, New York, NY, United States
⁴ Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, Hong Kong
⁵ Pfizer Inc, Collegeville, PA, United States
⁶ Pfizer Inc, Groton, CT, United States
⁷ Pfizer Inc, Tadworth, United Kingdom
⁸ Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada
⁹ University Hospitals Leuven, Leuven, Belgium

Topic
Endoscopy, IBD

Session
Hit the road JAK: Part 1

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)